Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Shepherd

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
The Journal of Infection|September 15, 2022
Risk factors for Crimean-Congo Haemorrhagic Fever (CCHF) virus exposure in farming communities in UgandaStella A Atim, Shirin Ashraf, Sandra Belij-Rammerstorfer, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Mutations in the HFE gene and cardiovascular disease risk: an individual patient data meta-analysis of 53 880 subjectsDaphne L van der A, Maroeska M Rovers, Diederick E Grobbee, et al.
Lancet (London, England)|May 27, 2008
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studiesNaveed Sattar, Alex McConnachie, A Gerald Shaper, et al.
BMJ (Clinical Research Ed.)|October 18, 2008
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial diseaseJill Belch, Angus MacCuish, Iain Campbell, et al.
Current Controlled Trials in Cardiovascular Medicine|July 5, 2002
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline CharacteristicsIan Ford, Gerard Jan Blauw, Michael B Murphy, et al.
Circulation|November 9, 2005
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)Chris J Packard, Ian Ford, Michele Robertson, et al.
Circulation|February 7, 2007
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Naveed Sattar, Heather M Murray, Alex McConnachie, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|September 30, 2006
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPSOlga A Iakoubova, Carmen H Tong, Anand P Chokkalingam, et al.
Lancet (London, England)|November 30, 2002
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialJames Shepherd, Gerard J Blauw, Michael B Murphy, et al.
The New England Journal of Medicine|October 23, 2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosisAmina Jindani, Thomas S Harrison, Andrew J Nunn, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
The Journal of Infection|September 15, 2022
Risk factors for Crimean-Congo Haemorrhagic Fever (CCHF) virus exposure in farming communities in UgandaStella A Atim, Shirin Ashraf, Sandra Belij-Rammerstorfer, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Mutations in the HFE gene and cardiovascular disease risk: an individual patient data meta-analysis of 53 880 subjectsDaphne L van der A, Maroeska M Rovers, Diederick E Grobbee, et al.
Lancet (London, England)|May 27, 2008
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studiesNaveed Sattar, Alex McConnachie, A Gerald Shaper, et al.
BMJ (Clinical Research Ed.)|October 18, 2008
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial diseaseJill Belch, Angus MacCuish, Iain Campbell, et al.
Current Controlled Trials in Cardiovascular Medicine|July 5, 2002
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline CharacteristicsIan Ford, Gerard Jan Blauw, Michael B Murphy, et al.
Circulation|November 9, 2005
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)Chris J Packard, Ian Ford, Michele Robertson, et al.
Circulation|February 7, 2007
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Naveed Sattar, Heather M Murray, Alex McConnachie, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|September 30, 2006
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPSOlga A Iakoubova, Carmen H Tong, Anand P Chokkalingam, et al.
Lancet (London, England)|November 30, 2002
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialJames Shepherd, Gerard J Blauw, Michael B Murphy, et al.
The New England Journal of Medicine|October 23, 2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosisAmina Jindani, Thomas S Harrison, Andrew J Nunn, et al.
Pageof 11